Clinical Trials for Parkinson’s Disease

  • J. K. Tsui
  • H. Teräväinen
  • D. B. Calne
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 88)


Anticholinergic agents have been used for over 100 years for treating Parkinson’s disease and clinical trials have been reported since the late nineteenth century (Aquilonius 1979). In the past two decades more drug studies have been conducted in Parkinson’s disease than in any other neurological disorder.


Essential Tremor Parkinsonian Motor Parkinsonian Gait Purdue Pegboard Homovanillic Acid Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armitage P (1957) Restricted sequential procedures. Biometrics 44: 9–26Google Scholar
  2. Armitage P (1960) Sequential medical trials. Blackwell, OxfordGoogle Scholar
  3. Aquilonius S-M (1979) Cholinergic mechanisms in the CNS related to Parkinson’s disease. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 17–27Google Scholar
  4. Barbeau A (1961) Biochemistry of Parkinson’s disease. In: Proceedings of the seventh international congress of neurology, Rome, Sept, Societa Grafica Romana, Rome, vol 2, p 925Google Scholar
  5. Barbeau A (1969) L-Dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med. Assoc J. 101: 791–800Google Scholar
  6. Barbeau A Roy M (1976) Six-year results of treatment with levodopa plus benzerazide in Parkinson’s disease. Neurology (NY) 267: 399–404Google Scholar
  7. Birkmayer W, Hornykiewicz O (1966) Der L-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788Google Scholar
  8. Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (= L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiatr Nervenkr 203: 560–574CrossRefGoogle Scholar
  9. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and L-deprenyl in Parkinson’s disease. Lancet 1: 439–443PubMedCrossRefGoogle Scholar
  10. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974). Bromocriptine in parkinsonism. Br Med J 4: 442–444PubMedCrossRefGoogle Scholar
  11. Canter GJ, deLa Torre R, Mier M (1961) A method for evaluating disability in patients with Parkinson’s disease. J Nerv Ment Dis 133: 143–147PubMedCrossRefGoogle Scholar
  12. Cotzias GC, Papavasilou PS, Gellene R (1969) Modification of parkinsonism—chronic treatment with L-dopa. N Engl J Med 280: 337–345PubMedCrossRefGoogle Scholar
  13. Donaldson J, LaBella FS, Gesser D (1980) Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity. Neurotoxicology (Park Forest II ) 2: 53–64Google Scholar
  14. Duvoisin RC (1970) The evaluation of extra-pyramidal disease. In: de Ajuriagerra J (ed) Monoamines: noyaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 313–325Google Scholar
  15. Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson’s disease. Neurology (NY) 31: 1356–1359Google Scholar
  16. England AC, Schwab RS (1956) Post-operative evaluation of selected patients with Parkinson’s disease. J Am Geriatr Soc 4: 1219–1232PubMedGoogle Scholar
  17. Evarts EV, Teravainen H, Calne DB (1981) Reaction time in Parkinson’s disease. Brain 106: 167–186CrossRefGoogle Scholar
  18. Fienbery SE (1983) The analysis of cross-classified categorial data, 2nd edn. MIT Press, CambridgeGoogle Scholar
  19. Folkerts JF, Njiokiktjien CJ (1971) The influence of L-dopa on the postural regulation of Parkinson patients. 1st Symposium international de posturographie, Madrid, 19–22 OctGoogle Scholar
  20. Hietanen M, Teravainen H, Tsui JK, Calne DB (1987) The pegboard as a measurement of parkinsonian motor deficit. Neurology 37 (Suppl 1): 266Google Scholar
  21. Hoaglin DC, Mosteller F, Tukey JW (1983) Understanding robust and exploratory data analysis. Wiley, New YorkGoogle Scholar
  22. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (NY) 17: 427–442Google Scholar
  23. Jansen EC, Larsen RE, Olesen MB (1982) Quantitative Romberg’s test. Acta Neurol Scand 66: 93–99PubMedCrossRefGoogle Scholar
  24. Kartzinel R, Perlow MD, Carter AC, Chase TN, Calne DB, Shoulson I (1976) Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington’s chorea. Trans Am Neurol Assoc 101: 53–56PubMedGoogle Scholar
  25. Knopp W (1968) Explorations in the assessment and meaning of the subclinical extrapyramidal effect of neuroleptic drugs. Pharmakopsychiatria Neuropsychopharmakol 1: 54–62Google Scholar
  26. Knutsson E (1972) An analysis of parkinsonian gait. Brain 95: 475–486PubMedCrossRefGoogle Scholar
  27. Lakke JPWF, Korf J, Van Praag HM, Schut T (1972) Predictive value of the probenecid test for the effect of L-dopa therapy in Parkinson’s disease. Nature New Biol 236: 208–209PubMedGoogle Scholar
  28. Larsen TA, LeWitt PA, Calne DB (1983) Theoretical and practical issues in assessment of deficits and therapy in parksinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 363–373Google Scholar
  29. Larsen TA, Calne S, Calne DB (1984) Assessment of Parkinson’s disease. Clin Neuropharmacol 7 (2): 165–169PubMedCrossRefGoogle Scholar
  30. Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J (1980) Evaluation of Parkinson’s disease. In: Goldstein M, Calne DB, Lieberman A, Thorner MO (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 277–286Google Scholar
  31. Lyman O (1984) An introduction to statistical methods and data analysis, 2nd ed Duxbury, BostonGoogle Scholar
  32. Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson’s disease. Neurology (NY) 31: 125–131Google Scholar
  33. Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Laihinen A, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB (1986) Positron emission tomography in Parkinson’s disease: glucose and DOPA metabolism. Adv Neurol 45: 95–101Google Scholar
  34. Parkes JD, Curzon G, Knott PJ, Tattersall R, Baxter RCH, Knill-Jones RP, Marsden CD, Vollum D (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet 1: 1083–1086PubMedCrossRefGoogle Scholar
  35. Schoenberg BS, Anderson DW, Haerer AF (1986) Racial differentials in the prevalence of Parkinson’s disease. Neural 36: 841–845Google Scholar
  36. Shoulson I, The Parkinson Sindy Group (1987). Correlates of clinical decline in early Parkinson’s disease (ABST). Neurology 37 (Suppl 1): 278Google Scholar
  37. Stoessl AJ, Mak E, Calne DB (1985) (+)-4-propyl-9-hydroxynaphthoxazine ( PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet ii: 1130–1331Google Scholar
  38. Tatton WG, Eastman MJ, Bedingham W, Verrier MC, Bruce IC (1984) Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 136–143PubMedGoogle Scholar
  39. Teräväinen H, Calne DB (1980) Quantitative assessment of Parkinsonian deficits. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease: current progress, problems and management. Elsevier, North-Holland, Amsterdam, pp 145–164Google Scholar
  40. Teräväinen H, Evarts EV, Calne DB (1980) Studies of parkinsonian movement. 1. Programming and execution of eye movements. Acta Neurol Scand 62: 137–148PubMedCrossRefGoogle Scholar
  41. Wagner HN, Burns HD, Dannais RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravart HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 264–1266CrossRefGoogle Scholar
  42. Ward CD, Sanes JN, Dambrosia JM, Calne DB (1983) Methods for evaluating treatment in Parkinson’s disease. Adv Neurol 37: 1–7PubMedGoogle Scholar
  43. Webster DD (1968) Critical analysis of the disability in Parkinson’s disease. Mod Treat 5: 257–282PubMedGoogle Scholar
  44. Webster DD, Mortimer JA (1977) Failure of L-dopa to relieve activated rigidity in Parkinson’s disease. In: Messiha FS, Kenny AD (eds) Parkinson’s disease. Neurophysiological, clinical and related aspects, Plenum, New York, pp 297–313.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. K. Tsui
  • H. Teräväinen
  • D. B. Calne

There are no affiliations available

Personalised recommendations